The unexpected consequences of generic entry

Micael Castanheira, Carmine Ornaghi and Georges Siotis

Journal of Health Economics, 2019, vol. 68, issue C

Abstract: Generic drugs are sold at a fraction of the original brand price. Yet, generic entry typically produces a drop in the quantity market share of the molecule losing exclusivity. This effect is economically and statistically significant for a large dataset covering hundreds of prescription drugs sold in the US during the period 1994Q1–2003Q4. This paper proposes the first systematic analysis of what appears to be a market anomaly.

Keywords: Non-price competition; Pharmaceutical industry; Generic entry; Consumer choice (search for similar items in EconPapers)
JEL-codes: D22 I11 L13 (search for similar items in EconPapers)
Date: 2019
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (18)

Downloads: (external link)
http://www.sciencedirect.com/science/article/pii/S0167629618305332
Full text for ScienceDirect subscribers only

Related works:
Working Paper: The Unexpected Consequences of Generic Entry (2019)
Working Paper: The Unexpected Consequences of Generic Entry (2019)
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:eee:jhecon:v:68:y:2019:i:c:s0167629618305332

DOI: 10.1016/j.jhealeco.2019.102243

Access Statistics for this article

Journal of Health Economics is currently edited by J. P. Newhouse, A. J. Culyer, R. Frank, K. Claxton and T. McGuire

More articles in Journal of Health Economics from Elsevier
Bibliographic data for series maintained by Catherine Liu ().